Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04131621
Title Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Heidelberg
Indications

squamous cell carcinoma

carcinoma

adenocarcinoma

Therapies

Nivolumab

Ipilimumab

Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.